NCT06379620View on ClinicalTrials.gov

Pilot Open Label Use of the Hi-OXSR for the Treatment of Post COVID-19 Cognitive Dysfunction

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

November 29, 2022

Primary Completion Date

March 4, 2024

Study Completion Date

March 4, 2024

Conditions
Post COVID-19 Condition
Interventions
DEVICE

Hi-OxSR Sequential Rebreathing mask (oxygen concentrator)

Subjects will self-administer oxygen gas at 1to 3LPM via a Hi-OxSR Sequential Rebreathing mask (oxygen concentrator), twice a day for 30 minutes with ventilation supplemented by the subject's rebreathed exhaled air. Total treatment is for 14 days

Trial Locations (1)

M5G 2C4

University Health Network, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER